

List of Tables

Table No.	Title	Page no.
2.1	Stages of reproductive aging workshop +10 staging system for reproductive aging in women	18
2.2	Summary of estrogen actions in various organs and effect of menopause	42
2.3	Common causes of vitamin b12 deficiency	45
2.4(a)	Various bioactive compounds, their functional sources and potential health benefits	70
2.4(b)	Various bioactive compounds, their functional sources and potential health benefits	71
2.4(c)	Various bioactive compounds, their functional sources and potential health benefits	72
2.5 (a)	Composition of macronutrient and their constituents in Indian flaxseed (brown) per 100g (Macronutrients)	75
2.5(b)	Composition of macronutrient and their constituents in Indian flaxseed (brown) per 100g (Types of carbohydrates)	75
2.5(c)	Composition of macronutrient and their constituents in Indian flaxseed (brown) per 100g (Fatty acid profile)	75
2.5(d)	Composition of macronutrient and their constituents in Indian flaxseed (brown) per 100g (Amino acid profile)	75
2.6 (a)	Composition of micronutrient and other compounds in Indian flaxseed (brown) per 100g (Vitamins)	76
2.6(b)	Composition of micronutrient and other compounds in Indian flaxseed (brown) per 100g (Minerals and trace minerals)	76
2.6(c)	Composition of micronutrient and other compounds in Indian flaxseed (brown) per 100g (Organic acids and polyphenols)	76
2.6(d)	Composition of micronutrient and other compounds in Indian flaxseed (brown) per 100g (Oligosaccharides, phytosterols, phytates and saponins)	76
2.7	ALA content of forty eight different flaxseed varieties of India	78
2.8	SDG (lignan) content of fifty different flaxseeds varieties of India	82
2.9(a)	Effect of flaxseeds and its various ingredients on metabolic aberrations	92
2.9(b)	Effect of flaxseeds and its various ingredients on metabolic aberrations	93



Table No.	Title	Page no.
2.9(c)	Effect of flaxseeds and its various ingredients on metabolic aberrations	94
2.9(d)	Effect of flaxseeds and its various ingredients on metabolic aberrations	95
2.9(e)	Effect of flaxseeds and its various ingredients on metabolic aberrations	96
2.9(f)	Effect of flaxseeds and its various ingredients on metabolic aberrations	97
3.1	Taxonomy of PKV-NL 260 variety of flaxseed	102
3.2	Inclusion and exclusion criteria for supplementation study	105
3.3	ALA content of two doses of flaxseed supplementation	107
3.4	Methods and tools used for data collection	110
3.5	WHO Asia Pacific Classification (2004) for body mass index (BMI)	116
3.6	Cut offs of abdominal obesity for women	117
3.7	JNC VIII classification for blood pressure	117
3.8	Cut-offs for percent body fat for women	118
3.9	NCEP ATP III (2001) criteria for diagnosing dyslipidemia	120
3.10	Cutoff values for lipid ratios	121
3.11	Cutoff values for atherogenic index of plasma	121
3.12	ADA 2011 guidelines for diagnosis of impaired glucose tolerance and diabetes	122
3.13	Metabolic syndrome IDF (2005) classifications for women	123
3.14	AHA/CDC reference range for HsCRP levels	124
3.15	WHO (2011) criteria for iron deficiency anemia in women	125
3.16	Measurement details and reference range for parameters/ indices under complete bold count	126
3.17	Cut off for vitamin B12 deficiency	129
3.18	Cut off for folic acid deficiency	129
3.19	Checkpoints for data monitoring and management	142
4.1	Basic characteristics of the screened women (n=408); (n,%)	146
4.2	Background information of the women (n, %)	148
4.3	Age-wise distribution of the women (n,%; Mean±SD)	149
4.4	Reproductive information of the women (Mean±SD; n,%)	149
4.5	General gastrointestinal ailments and nutritional deficiency symptoms reported by the women (n, %)	152
4.6	Life style habits reported by the women (n,%; Mean±SD)	152
4.7	Health care practices reported by the women (n, %)	154
4.8	Dietary practices of the women (n,%; Mean±SD)	155



Table No.	Title	Page no.
4.9	Average daily nutrient intake of the women (Mean \pm SD)	159
4.10	Mean values of various nutrients in pre and post-menopausal women (Mean \pm SD)	161
4.11	Frequency of consumption of trans fat rich food items (n=131)	163
4.12	Frequency of consumption of trans fat rich food items in pre-menopausal women (n=65)	164
4.13	Frequency of consumption of trans fat rich food items in post-menopausal women (n=66)	165
4.14	Highlights showing differences between life style, behavioural and dietary practices in pre and post-menopausal women	166
4.15	Family history and self-reported disease profile of the women (n, %)	175
4.16	Mean values of anthropometric and biophysical measurements of the women (Mean \pm SD)	177
4.17	Prevalence of overweight/obesity and hypertension in the women (n, %)	177
4.18	Lipid profile of the women (Mean \pm SD)	180
4.19	Prevalence of lipemic aberrations and atherogenic risk in the women (n, %)	180
4.20	Glycemic and inflammatory profile of the women (Mean \pm SD)	183
4.21	Prevalence of glycemic and inflammatory aberrations in the women (n, %)	183
4.22	Thyroid profile of the women (Mean \pm SD)	186
4.23	Prevalence of hypothyroidism in the women (N, %)	186
4.24	Haematological indices of the women (Mean \pm SD)	188
4.25	Prevalence of various indicators of nutritional anemia in the women (n, %)	190
4.26	Liver function tests of the women (Mean \pm SD)	192
4.27	Prevalence of liver function abnormalities in the women (n, %)	193
4.28	Kidney function tests of the women (Mean \pm SD)	194
4.29	Prevalence of kidney function abnormalities in the women (n, %)	194
4.30	Highlights showing association of menopause status with various physiological and metabolic aberrations	195
4.31	Comparison of mean values of various metabolic factors after adjusting for age and obesity (Mean \pm SD)	206



Table No.	Title	Page no.
4.32	Age and obesity adjusted analysis of effect of menopause on risk of developing metabolic aberrations using forward logistic regression	206
4.33	Highlights showing effect of obesity on physiological and metabolic aberrations in pre and post-menopausal women followed by age adjusted multivariate analyses	207
4.34	Frequency of consumption of vitamin b12 and folic acid rich food items (n=90) (n, %)	212
4.35	Prevalence of various causal factors of vitamin b12 deficiency in the women (n, %)	214
4.36	Independent causal factors of vitamin b12 deficiency in the women	217
4.37	Comparison of mean values of various risk parameters of ncds between vitamin b12 deficient and normal women (Mean \pm SD)	217
4.38	Prevalence of various risk factors of NCDs in relation to vitamin b12 status of the women (n, %)	218
4.39	Obesity and age adjusted association of vitamin b12 deficiency with risk factors of CVDs using logistic regression	218
4.40	Highlights showing major causal factors and metabolic aberrations associated with vitamin b12 deficiency	220
4.41	Correlation of HsCRP values with various variables in women	226
4.42	Comparison of mean values of the women with at risk and normal HsCRP levels (Mean \pm SD)	227
4.43	Prevalence of various conditions in relation to HsCRP values (N, %)	228
4.44	Forward logistic regression analysis for predictor variables of HsCRP	228
4.45	Highlights of association of HsCRP with various risk factors of NCDs	230
4.46	Correlation of HOMA IR values with various variables in non-diabetic women (n=79)	235
4.47	Comparison of mean values of variables stratified by insulin resistance (Mean \pm SD)	237
4.48	Prevalence of various conditions in relation to insulin resistance (n, %)	238
4.49	Forward logistic linear regression for predictor variables of HOMA IR	240
4.50	Highlights of association of HOMA IR with various risk factors of NCDs	241
4.51	Macronutrient content of the flaxseeds (PKV NL-260)	247
4.52	Mineral content of the flaxseeds (PKV NL-260) using ICP-OES	247
4.53	Phenolic content and antioxidant capacity of flaxseeds (PKV NL-260)	247



Table No.	Title	Page no.
4.54	Fatty acid profile of PKV NL-260 variety of flaxseeds using GC-MS	248
4.55	Characteristics of screened subjects (N, %)	257
4.56	Anthropometric and biophysical profile of the study subjects (N, %)	259
4.57	Prevalence of glycemic and inflammatory aberrations among the study subjects (N, %)	259
4.58	Prevalence of lipemic aberrations and atherogenic risk among the study subjects (N, %)	259
4.59	Prevalence of various indicators of iron deficiency anemia among the study subjects (N, %)	260
4.60	Prevalence of hypothyroidism among the study subjects (N, %)	260
4.61	Prevalence of liver function abnormalities among the study subjects (N, %)	260
4.62	Prevalence of kidney function abnormalities among the study subjects (N, %)	261
4.63	Mean values of various nutrient intake among the study subjects (Mean \pm SD)	261
4.64	Effect of flaxseed supplementation on the lipid profile of the study subjects	265
4.65	Effect of flaxseed supplementation on the atherogenic indices of the study subjects	266
4.66	Post hoc test lipid profile and atherogenic indices	266
4.67	Change in percent prevalence of lipid abnormalities among the study subjects	268
4.68	Impact of flaxseed supplementation on the lipid profile and atherogenic indices of the study subjects based on BMI (Mean \pm SD, mg/dl)	269
4.69	Impact of flaxseed supplementation on the lipid profile and atherogenic indices of the study subjects based on initial LDL levels (Mean \pm SD, mg/dl)	270
4.70	Impact of flaxseed supplementation on the lipid profile and atherogenic indices of the study subjects based on initial AIP levels (Mean \pm SD, mg/dl)	271
4.71	Impact of flaxseed supplementation on the lipid profile and atherogenic indices of the study subjects based on initial HsCRP levels (Mean \pm SD, mg/dl)	272
4.72	Impact of flaxseed supplementation on the lipid profile and atherogenic indices of the study subjects based on insulin resistance (Mean \pm SD, mg/dl)	273



Table No.	Title	Page no.
4.73	Summary table for effect of 5g flaxseeds supplementation on the lipid profile of the study subjects (% Difference)	274
4.74	Summary table for effect of 10g flaxseeds supplementation on the lipid profile of the study subjects (% Difference)	275
4.75	Summary table for changes in lipid profile of the study subjects under control group (% Difference)	276
4.76	Effect of flaxseed supplementation on the glycemic and inflammatory profile of the study subjects	279
4.77	Post hoc test for glycemic profile	280
4.78	Change in per cent prevalence of insulin resistance and inflammation among the study subjects	280
4.79	Impact of flaxseed supplementation on insulin resistance and inflammation of the study subjects based on BMI (Mean \pm SD)	282
4.80	Impact of flaxseed supplementation on the glycemic and inflammatory profile of the study subjects based on initial LDL levels (Mean \pm SD)	283
4.81	Impact of flaxseed supplementation on the glycemic and inflammatory profile of the study subjects based on initial AIP levels (Mean \pm SD)	284
4.82	Impact of flaxseed supplementation on the glycemic and inflammatory profile of the study subjects based on initial HsCRP levels (Mean \pm SD)	285
4.83	Impact of flaxseed supplementation on the glycemic and inflammatory profile of the study subjects based on insulin resistance (Mean \pm SD)	286
4.84	Summary table for effect of 5g flaxseeds supplementation on the glycemic and inflammatory profile of the study subjects (% Difference)	288
4.85	Summary table for effect of 10g flaxseeds supplementation on the glycemic and inflammatory profile of the study subjects (% Difference)	289
4.86	Summary table for changes in glycemic and inflammatory profile of the study subjects under control group (% Difference)	290
4.87	Effect of flaxseed supplementation on the anthropometric indices of the study subjects	292
4.88	Effect of flaxseed supplementation on the biophysical measurements of the study subjects	293



Table No.	Title	Page no.
4.89	Change in per cent prevalence of obesity and hypertension among the study subjects	295
4.90	Effect of flaxseed supplementation on the hematological indices of the study subjects	296
4.91	Post hoc test for hemoglobin	297
4.92	Change in per cent prevalence of iron deficiency anemia among the study subjects	297
4.93	Effect of flaxseed supplementation on the thyroid profile of the study subjects	299
4.94	Change in per cent prevalence of thyroid function abnormalities among the study subjects	299
4.95(a)	Effect of flaxseed supplementation on the liver function tests of the study subjects	300
4.95(b)	Effect of flaxseed supplementation on the liver function tests of the study subjects	301
4.96	Change in percent prevalence of liver function abnormalities among the study subjects	302
4.97	Effect of flaxseed supplementation on the kidney function tests of the study subjects	303
4.98	Post hoc test for kidney function tests	304
4.99	Change in per cent prevalence of kidney function abnormalities among the study subjects	304
4.100	Highlights of impact of flaxseed supplementation on biophysical, metabolic and inflammatory profile of women	305

